# US 2019/0292250 A1 · Aav-anti-vegf for treating cancer in companion animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292250 A1
- Document ID: US20190292250A1
- Status: Published application
- Kind: A1
- Application number: 15/754,939
- Filed: 2016-08-30
- Published: 2019-09-26
- Earliest claimed: 2015-08-31
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Christian Hinderer; James M. Wilson; Matthew Wilson
- Web page: https://patentgrep.com/patent/US20190292250A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 39/001135: {Vascular endothelial growth factor [VEGF]}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/552: {Veterinary vaccine}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/50: containing protease site
- C07K 2319/92: containing an intein ("protein splicing")domain
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2840/203: having an IRES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions and methods are provided for treating hemangiosarcoma in a subject. A recombinant AAV comprising a capsid and a vector genome comprising a nucleic acid expression cassette is provided. The expression cassette includes sequences encoding a promoter, a first signal peptide operably linked to an anti-VEGF antibody heavy chain immunoglobulin, a linker sequence, and a second signal peptide operably linked to an anti-VEGF light chain immunoglobulin, wherein said expression cassette co-expresses the immunoglobulin chains in a host cell under conditions which permit the chains to assemble into a functional anti-VEGF antibody. In one embodiment, the anti-VEGF antibody is a chimeric antibody.

## Claims

### Claim at position 1

1: A viral vector comprising at least one nucleic acid expression cassette comprising a nucleic acid sequence encoding a functional anti-VEGF antibody which binds canine VEGF which comprises an anti-VEGF antibody heavy chain immunoglobulin of SEQ ID NO: 15 and/or an anti-VEGF antibody light chain immunoglobulin of SEQ ID NO: 14, and expression control sequences which direct expression of the immunoglobulin chains in a host cell under conditions which permit the chains to assemble into the functional antibody.

### Claim at position 2

2: A viral vector comprising at least one nucleic acid expression cassette comprising a nucleic acid sequence encoding: a promoter, a first signal peptide operably linked to an anti-VEGF antibody heavy chain immunoglobulin, a linker sequence, and a second signal peptide operably linked to an anti-VEGF light chain immunoglobulin, wherein said expression cassette co-expresses the immunoglobulin chains in a host cell under conditions which permit the chains to assemble into a functional chimeric anti-VEGF antibody comprising SEQ ID NO: 14 and/or SEQ ID NO: 15.

### Claim at position 3 (depends on 1)

3: The viral vector of claim 1, wherein the viral vector is an adeno-associated viral vector.

### Claim at position 4 (depends on 3)

4: The viral vector of claim 3, wherein the vector has an AAV8 capsid.

### Claim at position 5 (depends on 2)

5: The viral vector of claim 2, wherein said linker sequence comprises one or more of an IRES sequence, a 2A peptide sequence and a furin site.

### Claim at position 6 (depends on 1)

6: The viral vector according to claim 1 wherein the chimeric anti-VEGF antibody is selected from a monoclonal antibody, an Fv, Fab, F(ab)2, F(ab)3, Fab′, Fab′-SH, F(ab′)2, an immunoadhesin, or a single chain variable fragment antibody.

### Claim at position 7 (depends on 5)

7: The viral vector of claim 5, wherein the antibody is a chimeric monoclonal antibody.

### Claim at position 8 (depends on 1)

8: The viral vector according to claim 1, wherein the nucleic acid sequence encoding anti-VEGF antibody heavy chain variable region comprises SEQ ID NO: 6 or a codon optimized variant thereof.

### Claim at position 9 (depends on 1)

9: The viral vector according to claim 1, wherein the nucleic acid sequence encoding anti-VEGF antibody heavy chain constant region comprises SEQ ID NO: 8 or a codon optimized variant thereof.

### Claim at position 10 (depends on 1)

10: The viral vector according to claim 1, wherein the nucleic acid sequence encoding anti-VEGF antibody light chain variable region comprises SEQ ID NO: 7 or a codon optimized variant thereof.

### Claim at position 11 (depends on 1)

11: The viral vector according to claim 1, wherein the nucleic acid sequence encoding anti-VEGF antibody light chain constant region comprises SEQ ID NO: 9 or a codon optimized variant thereof.

### Claim at position 12 (depends on 1)

12: The viral vector according to claim 1, wherein the promoter is a CMV promoter.

### Claim at position 13 (depends on 1)

13: The viral vector of claim 1, wherein the expression control sequences comprise a constitutive promoter.

### Claim at position 14 (depends on 1)

14: The viral vector according to claim 1, further comprising one or more of an intron, a Kozak sequence, a polyA, and a post-transcriptional regulatory elements.

### Claim at position 15 (depends on 1)

15: The viral vector according to claim 1, wherein AAV capsid is selected from AAV8, rh64R1, AAV9, AAVhu.37, or rh10 and variants thereof.

### Claim at position 16 (depends on 1)

16: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an rAAV according to claim 1.

### Claim at position 17 (depends on 16)

17: A method for treating cancer, said method comprising administering the composition of claim 16 to a subject in need thereof.

### Claim at position 18 (depends on 17)

18: The method according to claim 17, wherein said composition is administered at a dosage of about 1×1012 GC/kg.

### Claim at position 19

19: A chimeric anti-VEGF antibody comprising SEQ ID NO: 14 and SEQ ID NO: 15.

### Claim at position 20 (depends on 19)

20: The chimeric antibody of claim 19, wherein the nucleic acid sequence encoding said antibody comprises at least one of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, or a codon optimized variant thereof.

### Claim at position 21

21-22. (canceled)
